Study S002228

A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Single Escalating Oral Doses Of Pf-06882961 In Healthy Adult Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT03309241
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: TRIPLE
Status: COMPLETED
Enrollment: 25
Start: 2017-10-17
Primary completion: 2018-02-21
Lead sponsor: Pfizer
Conditions: Healthy Subjects
Interventions: DRUG:PF-06882961; OTHER:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Seriousness and Relationship to Treatment [First dose of study drug up to 28 days after last dose of study drug]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0008684	A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor. Griffith DA, Journal of medicinal chemistry	2022	Preclinical	PMID 35647711 DOI	cites ClinicalTrials.gov:NCT03309241
R0013378	A small-molecule oral agonist of the human glucagon-like peptide-1 receptor Griffith DA, bioRxiv	2020	Preclinical	DOI	cites ClinicalTrials.gov:NCT03309241
R0037191	Wolfenden Report H. Walker, BMJ	1959	Preclinical	DOI	cites ClinicalTrials.gov:NCT03309241